中文摘要：

目的：探讨内皮素-1（Endothelin-1，ET-1）与前列腺癌（PCa）的关系及其临床意义。方法：应用放射免疫分析法对31例PCa患者血浆中ET-1水平进行检测，其中新发PCa且对内分泌治疗敏感者（non-HRPC）23例，激素难治性PCa（HRPC）8例；以26例良性前列腺增生（BPH）患者作为对照，并作对比分析。结果：血浆ET-1水平在BPH组、未经治疗的PCa组及对雄激素治疗不敏感PCa组3组之间相互比较，差异均无显著性（P〉0．05）；在高、中分化PCa中血浆ET-1水平差异无显著性（P〉0．05），但显著高于低分化PCa（P〈0．05）；在骨转移癌和非骨转移癌之间差异无显著性；在PSA各分组之间的ET-1水平，差异无显著性（P〉0．05）。结论：血浆ET-1水平检测，未能反映PCa的发生发展和预后。

英文摘要：

Objective： To investigate plasma endothelin-1 （ET-1） level in patients with prostate cancers and its clinical significance. Methods： Plasma ET-1 level was measured by radioimmunoassay in 31 patients of prostate cancer （23 with non-HRPC, 8 with HRPC） and 26 patients of BPH. Results ： Compared with each other of the ET-1 level, there were no significant difference among the BPH group, non-HRPC group and HRPC group. No significant difference was found either between bone metastasis（BM） and non- BM, between high and middling differentiation prostate cancer group, as well as in different PSA level groups（ P 〉 0.05 ）. But the ET-1 level in low differentiation prostate cancer was notably lower than those of the high and middle respectively （ P 〈 0. 05 ）. Conclusion ： To detect plasma endotbelin-1 （ ET-1 ） level is not a useful method to evaluate the development and the prognosis of prostate cancer.